News from Nektar Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 18, 2017, 08:00 ET Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain

Nektar Therapeutics (NASDAQ: NKTR) announced positive topline results from an oral Human Abuse Potential (HAP) study of NKTR-181, a first-in-class...


Jul 10, 2017, 09:00 ET Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London

Nektar Therapeutics (NASDAQ: NKTR) today announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for...


Jun 06, 2017, 16:15 ET Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare...


Jun 05, 2017, 09:00 ET Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that it presented new findings from two Phase 1 clinical studies of NKTR-214, Nektar's lead...


May 22, 2017, 09:00 ET New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds

Nektar Therapeutics (NASDAQ: NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research...


May 15, 2017, 16:15 ET Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming UBS Global Healthcare Conference...


May 09, 2017, 16:10 ET Nektar Therapeutics Reports Financial Results for the First Quarter of 2017

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2017. Cash and investments in...


May 03, 2017, 09:15 ET Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program

Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Brian Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology...


May 02, 2017, 09:15 ET Nektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2017, on Tuesday, May 9, 2017, after...


Apr 20, 2017, 09:10 ET Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an analyst and investor event with clinical investigators on Saturday, June 3,...


Apr 04, 2017, 09:00 ET Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five preclinical data presentations for its immuno-oncology programs made at the American...


Mar 27, 2017, 09:00 ET Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders

Nektar Therapeutics (NASDAQ: NKTR) today announced that it has begun dosing in a Phase 1 clinical study evaluating NKTR-358, the company's new...


Mar 20, 2017, 07:30 ET NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid...


Mar 02, 2017, 19:01 ET Nektar to Webcast Presentation at Cowen and Company's 37th Annual Health Care Conference in Boston

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Cowen and Company 37th Annual...


Mar 01, 2017, 16:30 ET Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming American Association for Cancer...


Mar 01, 2017, 16:10 ET Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2016. Cash and...


Feb 22, 2017, 17:07 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2016, on Wednesday, March...


Feb 18, 2017, 19:24 ET Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in...


Jan 05, 2017, 09:00 ET Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 35th Annual...


Nov 14, 2016, 09:00 ET Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Jefferies 2016 London...


Nov 09, 2016, 14:30 ET Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented...


Nov 03, 2016, 16:10 ET Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2016. Cash and investments in...


Oct 28, 2016, 08:15 ET Nektar to Hold Investor & Analyst Event at 2016 Society for Immunotherapy of Cancer Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event at the upcoming Society for Immunotherapy of...


Oct 28, 2016, 08:00 ET Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for Immunotherapy of Cancer Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming Society for Immunotherapy of Cancer...


Oct 27, 2016, 16:15 ET Nektar to Announce Financial Results for the Third Quarter 2016 on Thursday, November 3, 2016, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2016, on Thursday, November 3,...